Methotrexate Adherence Tool in Rheumatoid Arthritis -METNA RA Study
Research type
Research Study
Full title
A cross-sectional, electronic survey to validate a new Methotrexate treatment adherence tool in Rheumatoid Athritis
IRAS ID
246651
Contact name
Thomas Stephen Hodges-Hoyland
Contact email
Sponsor organisation
F. Hoffmann-La-Roche
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 9 months, 0 days
Research summary
Adherence to medications is recognized as key for the successful therapy and for improving health outcomes. However, patients may in the presence of side effects or other reasons are known to adjust their treatment regimen leading to a potential detrimental effect on their health outcome.
For patients with rheumatoid arthritis (RA) being treated with a drug called Methotrexate (MTX), any tool that could be developed to increase adherence to treatment whilst improving doctor knowledge of the patient's experiences would lead to an overall improvement in disease management and health outcomes.
This study has been designed to validate the MTX experience questionnaire to aid Patient-Healthcare Provider communications and provide greater information to the scientific community regarding adherence to MTX. The study aims to provide a tool for clinical practice physicians that will not only allow the monitoring of adherence to MTX in routine clinical care but also for the identification of patients with poor adherence and/or experiencing compliance issues with MTX, among patients receiving MTX on an ongoing basis.
The patients adherence to MTX will be assessed by using subjective and objective data as follows:
Subjective assessments will include the newly developed MTX Experience Questionnaire to be completed by the patient and a physician evaluation of the patients adherence to the treatment regimen.
Objective assessments include measurement of the medication adherence using prescription data.REC name
London - Harrow Research Ethics Committee
REC reference
18/LO/0980
Date of REC Opinion
13 Jun 2018
REC opinion
Further Information Favourable Opinion